Connecticut

 

How The Inflation Reduction Act Lowers Prescription Drug Costs for Connecticuters

In 2022, Congressional Democrats passed and President Biden signed into law the Inflation Reduction Act, which allows Medicare to negotiate lower drug prices, limits annual out-of-pocket prescription drug costs, caps the price of insulin at $35 per month, offers no-cost vaccines to seniors, and more. The new law also holds accountable drug companies that hike the price of their drugs faster than inflation by requiring them to pay a rebate to Medicare.

 

The impact of lower prescription drug costs thanks to the Inflation Reduction Act will be felt by thousands of Connecticuters.

State Fact Sheet

 

Learn more about how the Inflation Reduction Act will help Connecticuters save on health care costs

Medicare Negotiations

Helping over 123,000 Connecticuters who pay hundreds or thousands out of pocket for the first 10 drugs Medicare is currently negotiating lower prices for.

full fact sheet

$2,000 Cost Cap

255,900 Connecticuters seniors will save an average of $367.55 thanks to the Inflation Reduction Act’s $2,000 annual out-of-pocket cost cap, effective in 2025.

full fact sheet

$35 Insulin Cost Cap

Helping 11,444 Connecticuters who use insulin.

full fact sheet

Negotiating lower prices on certain popular high-cost drugs will help:

  • 49,000 Connecticuters who pay an average of $433 out-of-pocket per year for Eliquis, sold by Bristol Myers Squibb, to treat blood clots. 
  • 19,000 Connecticuters who pay an average of $263 out-of-pocket per year for Jardiance, sold by Boehringer Ingelheim, to treat diabetes.
  • 19,000 Connecticuters who pay an average of $409 out-of-pocket per year for Xarelto, sold by Johnson & Johnson, to treat blood clots.
  • 13,000 Connecticuters who pay an average of $261 out-of-pocket per year for Januvia, sold by Merck, to treat diabetes. 
  • 8,000 Connecticuters who pay an average of $249 out-of-pocket per year for Farxiga, sold by AstraZeneca to treat diabetes.
  • 7,000 Connecticuters who pay an average of $349 out-of-pocket per year for Entresto, sold by Novartis, to treat heart failure. 
  • 1,000 Connecticuters who pay an average of $1,081 out-of-pocket per year for Enbrel, sold by Amgen, to treat arthritis and psoriasis.
  • Connecticuters who pay an average of $4,659 out-of-pocket per year for Imbruvica, sold by AbbVie, to treat blood cancers.
  • Connecticuters who pay an average of $1,447 out-of-pocket per year for Stelara, sold by Johnson & Johnson, to treat psoriasis and Crohn’s disease.
  • 7,000 Connecticuters who pay an average of $117 out-of-pocket per year for Fiasp/NovoLog, sold by Novo Nordisk, to treat diabetes.

Learn about another state: